Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6-11 Years of Age with Severe Atopic Dermatitis

• Главные авторы: Michael J. Cork (Автор), Diamant Thaçi (Автор), Lawrence F. Eichenfield (Автор), Peter D. Arkwright (Автор), Zhen Chen (Автор), Ryan B. Thomas (Автор), Matthew P. Kosloski (Автор), Ariane Dubost-Brama (Автор), Randy Prescilla (Автор), Ashish Bansal (Автор), Noah A. Levit (Автор)
• Формат: ‌
• Опубликовано: Adis, Springer Healthcare, 2023-09-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Abstract Background For children aged 6-11 years with uncontrolled severe atopic dermatitis (AD), 16 weeks of treatment with dupilumab resulted in substantial clinical benefit compared with placebo with an acceptable safety profile. However, longer-term safety and efficacy data are important to info...